Withdrawal of Flovent Led to Discontinuation of Inhaled Steroids for Children With Asthma
By Elana Gotkine HealthDay Reporter
FRIDAY, May 2, 2025 -- For children using fluticasone propionate, the withdrawal of the brand-name drug (Flovent) was associated with increased discontinuation of inhaled steroid therapy, according to a research letter published online April 26 in the Journal of the American Medical Association to coincide with the annual meeting of the Pediatric Academic Societies, held from April 24 to 28 in Honolulu.
Kao-Ping Chua, M.D., Ph.D., from the University of Michigan Medical School in Ann Arbor, and colleagues conducted a difference-in-differences analysis to examine whether the withdrawal of brand-name fluticasone propionate was associated with discontinuation of inhaled steroid therapy. The analyses included children aged 0 to 18 years with one or more dispensed inhaled steroid prescriptions in quarter 4 of 2021, 2022, and/or 2023. The treatment group included children for whom the only inhaled steroid prescriptions dispensed to them during these index quarters were for brand-name fluticasone propionate (1,980,963 person-years of data from 1,411,184 children), while the control group included children for whom the only inhaled steroid prescriptions dispensed during the index quarters were for other inhaled steroids, including the authorized generic fluticasone propionate (1,237,802 person-years of data from 969,268 children).
The researchers found that the treatment group experienced a 6.0 percentage point greater increase in the probability of having no inhaled steroid dispensing compared with the control group. Between 2021 and 2022, this probability increased 1.4 percentage points more in the control group versus the treatment group. Difference-in-differences estimates were larger among children aged 0 to 5 years versus older children and among Medicaid-insured children versus commercially insured children.
"Findings suggest that elimination of the Medicaid rebate cap was potentially associated with unintended consequences," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Passive Digital Marker Can Identify Childhood Asthma Risk
TUESDAY, June 17, 2025 -- It is feasible to use electronic health record (EHR) data in the Pediatric Asthma Risk Score (PARS) to accurately predict childhood asthma risk...
Multiple Environmental Exposures Jointly Contribute to Asthma Risk
WEDNESDAY, May 28, 2025 -- Air pollution, built environment, and ambient temperature jointly contribute to incident asthma risk, according to a study published online May 15 in...
Severe Exacerbations Down With As-Needed Albuterol-Budesonide for Mild Asthma
FRIDAY, May 23, 2025 -- As-needed albuterol-budesonide yields a lower risk for severe asthma exacerbation among patients with mild asthma, according to a study published online...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.